Biogen Q1 earnings: Leqembi sales improving slowly following lackluster launch
Biogen said sales of its Eisai-partnered Alzheimer’s drug Leqembi crept close to the $100 million mark in the first three months of the year, after the product fared worse than expected during its US launch ...
Biogen said sales of its Eisai-partnered Alzheimer’s drug Leqembi crept close to the $100 million mark in the first three months of the year, after the product fared worse than expected during its US launch ...
